These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10372529)

  • 1. In vivo proton magnetic resonance spectroscopy of diseased prostate: spectroscopic features of malignant versus benign pathology.
    García-Segura JM; Sánchez-Chapado M; Ibarburen C; Viaño J; Angulo JC; González J; Rodríguez-Vallejo JM
    Magn Reson Imaging; 1999 Jun; 17(5):755-65. PubMed ID: 10372529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo differential diagnosis of prostate cancer and benign prostatic hyperplasia: localized proton magnetic resonance spectroscopy using external-body surface coil.
    Kim JK; Kim DY; Lee YH; Sung NK; Chung DS; Kim OD; Kim KB
    Magn Reson Imaging; 1998 Dec; 16(10):1281-8. PubMed ID: 9858286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate.
    Kumar R; Kumar M; Jagannathan NR; Gupta NP; Hemal AK
    Urol Res; 2004 Feb; 32(1):36-40. PubMed ID: 14534764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue.
    Heerschap A; Jager GJ; van der Graaf M; Barentsz JO; de la Rosette JJ; Oosterhof GO; Ruijter ET; Ruijs SH
    Anticancer Res; 1997; 17(3A):1455-60. PubMed ID: 9179183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy.
    Kurhanewicz J; Vigneron DB; Nelson SJ; Hricak H; MacDonald JM; Konety B; Narayan P
    Urology; 1995 Mar; 45(3):459-66. PubMed ID: 7533458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution.
    Kurhanewicz J; Vigneron DB; Hricak H; Narayan P; Carroll P; Nelson SJ
    Radiology; 1996 Mar; 198(3):795-805. PubMed ID: 8628874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer: metabolic response to cryosurgery as detected with 3D H-1 MR spectroscopic imaging.
    Kurhanewicz J; Vigneron DB; Hricak H; Parivar F; Nelson SJ; Shinohara K; Carroll PR
    Radiology; 1996 Aug; 200(2):489-96. PubMed ID: 8685346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of human prostate cancer, benign prostatic hyperplasia and normal prostate by in vitro 1H and 31P magnetic resonance spectroscopy.
    Cornel EB; Smits GA; Oosterhof GO; Karthaus HF; Deburyne FM; Schalken JA; Heerschap A
    J Urol; 1993 Dec; 150(6):2019-24. PubMed ID: 7693985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel biomarker for prostate cancer diagnosis by MRS.
    Sarkar BK; Chakraborty C; Sharma AR; Bae KJ; Sharma G; Doss GP; Dutta D; Ding S; Ganbold B; Nam JS; Lee SS
    Front Biosci (Landmark Ed); 2014 Jun; 19(7):1186-201. PubMed ID: 24896344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance spectroscopic imaging of benign prostatic tissue: findings at 3.0 T compared to 1.5 T-initial experience.
    Chitkara M; Westphalen A; Kurhanewicz J; Qayyum A; Poder L; Reed G; Coakley FV
    Clin Imaging; 2011; 35(4):288-93. PubMed ID: 21724122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
    Zbýň Š; Krššák M; Memarsadeghi M; Gholami B; Haitel A; Weber M; Helbich TH; Trattnig S; Moser E; Gruber S
    Rofo; 2014 Jul; 186(7):698-702. PubMed ID: 24940925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using endorectal 1H magnetic resonance spectroscopy].
    Saikawa S; Suzuki Y; Tomoi M; Yoshida M; Ishii Y; Okada K
    Nihon Hinyokika Gakkai Zasshi; 1995 Nov; 86(11):1673-80. PubMed ID: 8551711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic characterization of human prostate tissue with proton MR spectroscopy.
    Swindle P; McCredie S; Russell P; Himmelreich U; Khadra M; Lean C; Mountford C
    Radiology; 2003 Jul; 228(1):144-51. PubMed ID: 12832578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report.
    Narayan P; Jajodia P; Kurhanewicz J; Thomas A; MacDonald J; Hubesch B; Hedgcock M; Anderson CM; James TL; Tanagho EA
    J Urol; 1991 Jul; 146(1):66-74. PubMed ID: 1711587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton MR spectroscopy of the prostate.
    Mueller-Lisse UG; Scherr MK
    Eur J Radiol; 2007 Sep; 63(3):351-60. PubMed ID: 17709223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MR characteristics of prostatic carcinoma and benign prostatic hyperplasia at 1.5 T.
    Griebel J; Hess CF; Schmiedl U; Koelbel G
    J Comput Assist Tomogr; 1988; 12(6):988-94. PubMed ID: 2460511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation between benign prostatic hyperplasia and prostate cancer in the transitional zone evaluated by 1H magnetic resonance spectroscopic imaging.
    Li SY; Chen M; Wang R; Zhou C
    Chin Med Sci J; 2007 Dec; 22(4):238-42. PubMed ID: 18246671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of metabolite concentrations in benign and malignant prostate tissues using 3D proton MR spectroscopic imaging.
    Weis J; von Below C; Tolf A; Ortiz-Nieto F; Wassberg C; Häggman M; Ladjevardi S; Ahlström H
    J Magn Reson Imaging; 2017 Apr; 45(4):1232-1240. PubMed ID: 27556571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro high resolution 1H-spectroscopy of the human prostate: benign prostatic hyperplasia, normal peripheral zone and adenocarcinoma.
    Schiebler ML; Miyamoto KK; White M; Maygarden SJ; Mohler JL
    Magn Reson Med; 1993 Mar; 29(3):285-91. PubMed ID: 7680746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MR spectroscopy as a reliable diagnostic tool for localization of prostate cancer.
    Hasumi M; Suzuki K; Oya N; Ito K; Kurokawa K; Fukabori Y; Yamanaka H
    Anticancer Res; 2002; 22(2B):1205-8. PubMed ID: 12168926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.